No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
Aged
Aged, 80 and over
Axons
/ metabolism
Corpus Striatum
/ metabolism
Dopamine
/ metabolism
Dopamine Plasma Membrane Transport Proteins
/ metabolism
Female
Humans
Male
Middle Aged
Neurons
/ metabolism
Parkinson Disease
/ complications
Putamen
/ metabolism
Substantia Nigra
/ metabolism
Tomography, Emission-Computed, Single-Photon
/ methods
Parkinson's disease
SPECT
dopamine transporter
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
14
03
2019
revised:
29
05
2019
accepted:
31
05
2019
pubmed:
25
6
2019
medline:
13
6
2020
entrez:
25
6
2019
Statut:
ppublish
Résumé
Brain dopamine transporter binding has been considered a possible biomarker for nigrostriatal degeneration in PD. To investigate whether dopamine transporter binding is associated with the number of dopaminergic neurites in the putamen. Tyrosine hydroxylase-positive nerve fibers were counted from postmortem putamen sections taken from 14 parkinsonism patients who had been scanned with dopamine transporter single-photon emission computed tomography antemortem. Fiber counts were correlated with putamen dopamine transporter binding and SN neuron counts. The putamen dopamine transporter specific binding ratio did not correlate with the putamen tyrosine hydroxylase-positive axon counts (r = 0.00; P = 1.0; PD patients: r = 0.07; P = 0.86). The nigra neuron counts had a positive correlation with the putamen tyrosine hydroxylase-positive axon counts. Striatal dopamine transporter imaging does not associate with axonal nor somal loss of the nigrostriatal neurons in PD. It may reflect dopaminergic activity rather than number of surviving neurons or their striatal projection axons. © 2019 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Brain dopamine transporter binding has been considered a possible biomarker for nigrostriatal degeneration in PD.
OBJECTIVE
To investigate whether dopamine transporter binding is associated with the number of dopaminergic neurites in the putamen.
METHODS
Tyrosine hydroxylase-positive nerve fibers were counted from postmortem putamen sections taken from 14 parkinsonism patients who had been scanned with dopamine transporter single-photon emission computed tomography antemortem. Fiber counts were correlated with putamen dopamine transporter binding and SN neuron counts.
RESULTS
The putamen dopamine transporter specific binding ratio did not correlate with the putamen tyrosine hydroxylase-positive axon counts (r = 0.00; P = 1.0; PD patients: r = 0.07; P = 0.86). The nigra neuron counts had a positive correlation with the putamen tyrosine hydroxylase-positive axon counts.
CONCLUSIONS
Striatal dopamine transporter imaging does not associate with axonal nor somal loss of the nigrostriatal neurons in PD. It may reflect dopaminergic activity rather than number of surviving neurons or their striatal projection axons. © 2019 International Parkinson and Movement Disorder Society.
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
SLC6A3 protein, human
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1562-1566Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
Tagliaferro P, Burke RE. Retrograde axonal degeneration in Parkinson disease. J Parkinsons Dis 2016;6:1-15.
Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136(Pt 8):2419-2431.
Fazio P, Svenningsson P, Cselényi Z, Halldin C, Farde L, Varrone A. Nigrostriatal dopamine transporter availability in early Parkinson's disease. Mov Disord 2018;33:592-599.
Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 2017;88:1461-1467.
Jankovic J. Parkinson's disease tremors and serotonin. Brain 2018;141:624-626.
Joutsa J, Gardberg M, Röyttä M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonsim Relat Disord 2014;20:840-844.
Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 2014;29:1767-1773.
Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol 2017;82:873-882.
Tian L, Karimi M, Brown CA, Loftin SK, Perlmutter JS. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. Brain Res 2014;1571:49-60.
Shimony JS, Rutlin J, Karimi M, et al. Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques. PLoS One 2018;13:e0202201.
Blesa J, Pifl C, Sánchez-González MA, et al. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. Neurobiol Dis 2012;48:79-91.
Karimi M, Tian L, Brown CA, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013;73:390-396.
Leviel V. Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem 2011;118:475-489.